Loading...
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.
Ford, H Marshall, A Bridgewater, J Janowitz, T Coxon, F Wadsley, J Mansoor, Was Fyfe, D Madhusudan, S Middleton, G
Ford, H
Marshall, A
Bridgewater, J
Janowitz, T
Coxon, F
Wadsley, J
Mansoor, Was
Fyfe, D
Madhusudan, S
Middleton, G
Citations
Altmetric:
Abstract
Second-line chemotherapy for patients with oesophagogastric adenocarcinoma refractory to platinum and fluoropyrimidines has not shown benefits in health-related quality of life (HRQoL). We assessed whether the addition of docetaxel to active symptom control alone can improve survival and HRQoL for patients.
Affiliation
Description
Date
2014-01
Publisher
Collections
Keywords
Type
Article
Citation
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. 2014, 15 (1):78-86 Lancet Oncol